Abstract: The present invention relates to a method for the treatment of copper-bearing materials, such as copper concentrates, so that the impurities and gangue minerals in the materials, such as silicates, are in effect removed completely.

Abstract: The present invention provides an improved process for the preparation of MgO of high purity >99% from salt bitterns via intermediate formation of Mg(OH)2 obtained from the reaction of MgCl2 and lime, albeit indirectly, i.e., MgCl2 is first reacted with NH3 in aqueous medium and the slurry is then filtered with ease. The resultant NH4Cl-containing filtrate is then treated with any lime, to regenerate NH3 while the lime itself gets transformed into CaCl2 that is used for desulphatation of bittern so as to recover carnallite and thereafter MgCl2 of desired quality required in the present invention. The crude Mg(OH)2 is dried and calcined directly to produce pure MgO, taking advantage of the fact that adhering impurities in the Mg(OH)2 either volatilize away or get transformed into the desired product, i.e., MgO.

Abstract: Nitrogen oxides (NOx) storage catalysts comprising cobalt and barium with a lean NOx storage ratio of 1.3 or greater. The NOx storage catalysts can be used to reduce NOx emissions from diesel or gas combustion engines by contacting the catalysts with the exhaust gas from the engines. The NOx storage catalysts can be one of the active components of a catalytic converter, which is used to treat exhaust gas from such engines.

Abstract: Systems and methods using the properties of supercritical water to allow raw air including a contaminant to be combined with water and to be purified in a supercritical water oxidation (SCWO) process. A supercritical water oxidation (SCWO) air purifier will generally take in a mixture of water and raw air which includes oxygen via a pumping and mixing apparatus, put the mixture into a supercritical water reactor (SCWR), and run the resultant effluent stream through a system for separating the water from the resultant clean air and the other relatively harmless outputs of the supercritical water reactor (SCWO).

Abstract: The method allows to remove mercaptans contained in a gaseous feed comprising hydrocarbons by carrying out the following stages: a) contacting, in a reactor R1, gaseous feed 1 with a liquid stream 13 comprising olefins, in the presence of a first acid catalyst so that the mercaptans react with the olefins so as to form sulfides, b) discharging an effluent 3 from reactor R1 and separating the effluent into a gas phase and a liquid phase so as to obtain a mercaptan-depleted treated gas 4 and a sulfide-laden liquid, c) separating the sulfide-laden liquid into a first fraction 6 and a second fraction 5, the volume flow rate of first fraction 6 being at least three times higher than the volume flow rate of second fraction 5, d) recycling first fraction 6 to stage a) as a first portion of said liquid stream to be fed into said reactor R1, e) regenerating second fraction 5 by cracking so as to obtain a sulfide-depleted second fraction 2 that is recycled to stage a) as a second portion of said liquid stream.

Abstract: A filter device and method for using a filter device. The filter device includes a catalyst for catalyzing the reaction of organic molecules, such as an oxidation reaction, and an adsorbent for adsorbing reacted organic molecules. As a result, gaseous contaminants that include organic molecules are reacted to alter the polarity and reduce the molecular weight of the molecules. The reacted molecules are then adsorbed using an adsorbent. The filter and method are particularly useful for reacting and capturing hydrocarbons such as aliphatic hydrocarbons from an enclosed space, such as a disk drive assembly.

Abstract: The invention provides a method of preparing hydrophobic silica particles comprising (a) providing an aqueous colloidal silica dispersion comprising about 5-70 wt. % of silica particles having an average overall particle size of about 10-1000 nm, wherein the silica particles comprise surface silanol groups, (b) combining the silica dispersion with about 3-75 ?mole/m2 (based on the BET surface area of the silica) of a silyl amine treating agent and optionally with other ingredients to provide a reaction mixture, wherein the reaction mixture has a pH of about 7 or more, and comprises no more than about 50 wt. % of an organic solvent, and (c) drying the dispersion to provide hydrophobic silica particles. The invention further provides a method of preparing a toner composition comprising combining the hydrophobic silica particles as recited above with toner particles to provide a toner composition.

Abstract: The invention relates to a method of making alkali metal silicide compositions, and the compositions resulting from the method, comprising mixing an alkali metal with silicon and heating the resulting mixture to a temperature below about 475° C. The resulting compositions do not react with dry O2. Also, the invention relates to sodium silicide compositions having a powder X-ray diffraction pattern comprising at least three peaks with 2Theta angles selected from about 18.2, 28.5, 29.5, 33.7, 41.2, 47.4, and 56.2 and a solid state 23Na MAS NMR spectra peak at about 18 ppm. Moreover, the invention relates to methods of removing a volatile or flammable substance in a controlled manner. Furthermore, the alkali metal silicide compositions of the invention react with water to produce hydrogen gas.

Abstract: A method for making carbon nanotube particulates involves providing a catalyst comprising catalytic metals, such as iron and molybdenum or metals from Group VIB or Group VIIIB elements, on a support material, such as magnesia, and contacting the catalyst with a gaseous carbon-containing feedstock, such as methane, at a sufficient temperature and for a sufficient contact time to make small-diameter carbon nanotubes having one or more walls and outer wall diameters of less than about 3 nm. Removal of the support material from the carbon nanotubes yields particulates of enmeshed carbon nanotubes that retain an approximate three-dimensional shape and size of the particulate support that was removed. The carbon nanotube particulates can comprise ropes of carbon nanotubes. The carbon nanotube particulates disperse well in polymers and show high conductivity in polymers at low loadings. As electrical emitters, the carbon nanotube particulates exhibit very low “turn on” emission field.

Abstract: A method and apparatus for producing surface stabilized nanometer-sized particles includes the steps of mixing reactants, a surface-stabilizing surfactant, and a high boiling point liquid to form a mixture, continuously passing the mixture through an ultrasonic spray nozzle to form a mist of droplets of the mixture, injecting the mist directly into a furnace to cause a reaction between species of the mixture, and collecting the nanometer-sized products. The ultrasonic nozzle is positioned directly at one end of the heating furnace, preferably the top end, for travel of the droplets through the furnace. The continuous liquid-flow process, along with certain operating parameters, eliminates the need for dilution of the high boiling point liquid with a low boiling point solvent as in the prior art, significantly increases the yield, improves the quality of the product, and makes the process scalable.

Abstract: A method for recovering sulfur from a sulfur-bearing process gas stream in which a process gas stream comprising H2S and/or SO2 is contacted with a lean mixture of a lean UCSRP solution and a catalyst for promotion of a reaction between H2S and SO2 in anon-UCSRP vessel at a temperature below which H2S and SO2 react, whereby at least a portion of the H2S and/or SO2 is absorbed by the lean UCSRP solution, forming a rich mixture of a rich UCSRP solution and the catalyst. The rich mixture is introduced into a UCSRP vessel and heated to a reaction temperature greater than or equal to a melting temperature of sulfur, forming elemental sulfur and H2O.

Abstract: The present invention is directed to a process for making nanoparticles of metals, metal alloys, metal oxides and multi-metallic oxides, which comprises the steps of reacting a metal salt dissolved in water with an alkali metal salt of C4-25 carboxylic acid dissolved in a first solvent selected from the group consisting of C5-10 aliphatic hydrocarbon and C6-10 aromatic hydrocarbon to form a metal carboxylate complex; and heating the metal carboxylate complex dissolved in a second solvent selected from the group consisting of C6-25 aromatic, C6-25 ether, C6-25 aliphatic hydrocarbon and C6-25 amine to produce the nanoparticles.

Abstract: Aluminum hydroxide aggregated particles which have an average particle diameter of not less than 40 ?m, an average particle diameter as determined after pressing at 1,000 kg/cm2 of not more than 35 ?m, and an L value of slurry obtained by mixing 20 ml of glycerol and 10 g of the aluminum hydroxide aggregated particles of not more than 69, are obtained by a process comprising the steps of: (a) feeding a supersaturated aqueous sodium aluminate solution to a vessel, (b) adding aluminum hydroxide seeds to the supersaturated aqueous sodium aluminate solution, (c) stirring the seed-added solution in the vessel while continuously feeding an additional supersaturated aqueous sodium aluminate solution into the vessel to hydrolyze the supersaturated aqueous sodium aluminate solution, (d) separating the aluminum hydroxide aggregated particles from the aqueous sodium aluminate solution, and (e) continuously discharging the aqueous sodium aluminate solution out of the vessel.

Abstract: The present invention relates to a method for preparing a uniformly aligned zeolite supercrystal, which comprises growing a crystal of a zeolite or zeotype material in a uniformly aligned template, whereby said uniformly aligned zeolite supercrystal is prepared, and a uniformly aligned zeolite supercrystal. The uniformly aligned zeolite supercrystal of this invention would be anticipated to maximize its applicability by overcoming the shortcomings of zeolites with random orientation.

Abstract: The invention generally relates to novel fluorescent phospholipid compounds and compositions comprising these compounds.

Abstract: Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, both at dosages below their respective single agent dosages, for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented are compositions, unit dosage forms, and kits that are useful in performing the methods.

Abstract: This invention comprises nanoparticles for use with biosensors. The nanoparticles have core/shell architecture. The nanoparticles can be detected by two means, magnetic and optical by virtue of the nanoparticles magnetic core and fluorescent semiconductor shell. Methods of making the nanoparticles and their composition are described.

Abstract: The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma.

Abstract: A cosmetic composition for treating keratin fibers, such as the hair, comprising: at least one anionic surfactant; at least one second surfactant chosen from amphoteric and zwitterionic surfactants; at least one first cationic polymer chosen from cationic polysaccharides; and at least one second cationic polymer chosen from dialkyldiallylammonium homopolymers and copolymers; and at least one non-amino non-volatile silicone, and treatment processes using the composition.

Abstract: Razors and components thereof are provided, as well as methods of making such.

Abstract: The horse liniment is a veterinary composition for topical application for the relief of muscle and joint pain in horses. The composition contains, by weight, about 49% alcohol, 20% olive oil, 10% arnica, 14% creosote, 1% iodine, 2% turpentine, 2% camphor, and 2% alum. The ingredients may be mixed at room temperature, the powdered ingredients being soluble in the alcohol-olive oil base. The composition is applied topically to the affected muscles or joints in conventional manner as needed. The composition has been found to be effective, often with a single application, with increased range of motion, an absence or reduction of limping, increased energy, and other signs of a healthy, active horse.

Abstract: The present invention discloses a tri-branched copolymer comprising a hydrophobic domain, a hydrophilic domain, a biologically active moiety, and an alkyl core of 2 to 10 carbon atoms. The hydrophobic domain, the hydrophilic domain, and the biologically active moiety are separately linked to the alkyl core of 2 to 10 carbon atoms through three functional groups, wherein said three functional groups are independently the same or different. Preferably, the tri-branched copolymer is prepared through reversible addition fragmentation transfer (RAFT) polymerization and conjugation reactions. The present invention also discloses a coating composition for applying on at least a portion of one surface of an article. The coating composition comprises the inventive tri-branched copolymer. In another aspect, the present invention discloses an article having the inventive coating composition thereon. Preferably, the article is a medical device or a component of a medical device.

Abstract: A copolymer or a pharmacologically acceptable salt thereof is provided, which contains, as constitutional units, (a) one or more structural units of formula (I): wherein m is an integer of from 3 to 100, Alk represents alkyline, and R1 and R2 are the same or different and each represents hydrogen or optionally substituted alkyl, and (b) one or more structural units of formula (II): wherein R3 represents hydroxyl, optionally substituted alkoxy, optionally substituted aryloxy, or a group represented by the formula —NR4R5, wherein R4 and R5 are the same or different and each represents hydrogen or optionally substituted alkyl.

Abstract: Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells.

Abstract: The present invention provides compositions comprising freeze-dried platelets, microparticles, or both for use as a hemostat, such as for treating bleeding or injuries associated with bleeding. It also provides methods of treating injuries or wounds, and methods of causing blood to clot. Likewise, it provides methods of promoting healing of wounds or of healing wounds.

Abstract: The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.

Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.

Abstract: A novel gene, designated MCT-1 (for Multiple Copies in T-cell malignancy), is provided. A protein encoded by MCT-1, designated MCT-1, is also provided. Antisense oligonucleotides complementary to or homologous with a portion of MCT-1, substantially purified MCT-1, and methods of determining whether a cell is a tumor cell are also provided. The invention also includes monoclonal and polyclonal antibody preparations which bind with specificity to MCT-1. The invention further includes methods of determining whether a compound or a gene product is a modulator of MCT-1 expression, a method of reducing MCT-1 expression in a cell, and a method of conferring a growth advantage on a cell.

Abstract: The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.

Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.

Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.

Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.

Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

Abstract: Humanized monoclonal antibodies against the vaccinia virus B5R surface antigen. The antibodies are effective in treating smallpox infection. Also disclosed are nucleic acids that encode the heavy and light chains of such antibodies and cells that express them.

Abstract: The present invention relates to a recombinant human antibody comprising an antibodysequence specific for the MSP-3 antigen of Plasmodium falciparum. In particular, the invention relates to a recombinant human antibody which is specific for the MSP-3194-257 antigen. The invention further relates to nucleic acid encoding such antibodies and to uses of these antibodies, in particular in the treatment or prophylaxis of malaria.

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract: Polyallylamine conjugates and applications thereof for biological signal amplification are provided by utilizing the essential amino group of polyallylamine to covalently bind with capture agents and signal molecules having the functional groups selected from a group consisting of —NHS, —CO, —S?O2 and —C?O—C?O. The resulting conjugates having more than one signaling entities can be further implemented for biological expression with enhancing effect on biological signal intensity, such that the sensitivity of detection for the variation between biological interactions is largely increased.

Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.

Abstract: The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module with one or more of the following features: antigen, adjuvant and targeting-delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular, it is claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens, to prime or to boost protective immune responses against itself as well as other antigens and/or to selectively deliver these antigen(s) as well as active compounds to dendritic cells, endothelial cells and macrophages, due to its capability of targeting these A PC and of activating their maturation and functions and of increasing Th-1 type immune responses as an adjuvant.

Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal, breast, and lung cancers, autoimmune diseases, and related conditions.

Abstract: A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides.

Abstract: Described herein are chimeric peptides comprising a soluble trimeric coiled-coil and all or a portion of the N-peptide region of HIV gp41. These molecules are stable, trimeric coiled-coils that inhibit HIV entry into cells, such as human cells. Such peptides can be further assessed to demonstrate their ability to serve as potent anti-HIV therapeutic molecules and thus, as therapeutic molecules or drugs.

Abstract: The present invention relates to a novel genomic RNA of Japanese encephalitis virus (JEV) and an infectious JEV cDNA therefrom. Particularly, the present invention relates to a full-length genomic RNA of JEV represented by SEQ. ID. No 15 and an infectious JEV cDNA therefrom. JEV genomic RNA and infectious JEV cDNA of the present invention can be used not only for the identification of the JEV genes, but also for the molecular biological studies including JEV replication, transcription, and translation. Moreover, they can also be applied to the development of the therapeutic agents, vaccines, diagnostic reagents, and diagnostic devices for Japanese encephalitis, and can be used as an expression vector for the various foreign genes.

Abstract: Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are important in virus neutralization. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.

Abstract: Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the outer cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth.

Abstract: An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus.

Abstract: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention also discloses vaccines that can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.